Form 4 for GNLX GENELUX Corp
Accepted 2023-09-21 00:00:00 ET · period of report 2023-09-20 · accession 0001209191-23-050282 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-09-21 | 2023-09-20 | GNLX | Yu Yong | VP, Clinical Trial Ops | M - OptEx | $6.00 | +6,000 | 112.1K | +6% | +$36.0K |
| D | 2023-09-21 | 2023-09-20 | GNLX | Yu Yong | VP, Clinical Trial Ops | S - Sale+OE | $27.96 | -6,000 | 106.1K | -5% | -$167.8K |
| D | 2023-09-21 | 2023-09-20 | GNLX | Yu Yong | VP, Clinical Trial Ops | M - OptEx | $0.00 | -6,000 | 223.3K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-20 | M | A | 6,000 | $6.00 | 112,135 | D | — | — | |
| 2 | Common | Common Stock | 2023-09-20 | S | D | 6,000 | $27.96 | 106,135 | D | — | — | (F2) The weighted average sale price for the transaction reported was $27.9643, and the range of prices were between $27.95 and $28.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 3 | Derivative | Stock Option (right to buy) | 2023-09-20 | M | D | 6,000 | $0.00 | 223,253 | D | $6.00 · — to 2029-09-20 | 6,000 Common Stock | (F3) Immediately exercisable. |